Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis

Cardoso, Rhanderson; Ternes, Caique Martins Pereira; Justino, Gustavo Busch; Fernandes, Amanda; Rocha, A. C.; Knijnik, Leonardo; Reddy, Vivek Y.; Lópes, Renato D.

doi:10.1016/j.amjmed.2021.08.026

Cited by 11 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation (RIVER) study suggested that rivaroxaban was non-inferior to warfarin in AF patients with bioprosthetic mitral valves. [138] A meta-analysis based on RCTs also demonstrated that the use of NOACs, compared to warfarin, significantly reduced the risk of stroke, systemic embolism, and major bleeding in patients with AF and bioprosthetic valves or prior valve repair. [139] The Edoxaban vs. Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation-AF (ENVISAGE-TAVI AF) study demonstrated that when used in AF patients undergoing successful transcatheter aortic valve replacement (TAVR), edoxaban was non-inferior to warfarin in reducing the risk of a postoperative major adverse cardiovascu-…”

Section: Patients With Af and Valvular Heart Diseasementioning

confidence: 99%

Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

MA,

WU,

LIU

et al. 2024

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly impacting patients' quality of life and increasing the risk of death, stroke, heart failure, and dementia. Over the past two decades, there have been significant breakthroughs in AF risk prediction and screening, stroke prevention, rhythm control, catheter ablation, and integrated management. During this period, the scale, quality, and experience of AF management in China have greatly improved, providing a solid foundation for the development of guidelines for the diagnosis and management of AF. To further promote standardized AF management, and apply new technologies and concepts to clinical practice in a timely and comprehensive manner, the Chinese Society of Cardiology of the Chinese Medical Association and the Heart Rhythm Committee of the Chinese Society of Biomedical Engineering have jointly developed the Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation. The guidelines have comprehensively elaborated on various aspects of AF management and proposed the CHA 2 DS 2 -VASc-60 stroke risk score based on the characteristics of AF in the Asian population. The guidelines have also reevaluated the clinical application of AF screening, emphasized the significance of early rhythm control, and highlighted the central role of catheter ablation in rhythm control.

show abstract

Section: Patients With Af and Valvular Heart Diseasementioning

confidence: 99%

Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

MA,

WU,

LIU

et al. 2024

Journal of Geriatric Cardiology

View full text Add to dashboard Cite

show abstract

“…138 A metaanalysis based on RCTs also demonstrated that the use of NOACs, compared to warfarin, significantly reduced the risk of stroke, systemic embolism, and major bleeding in patients with AF and bioprosthetic valves or prior valve repair. 139 The Edoxaban versus Standard of Care and Their Effects on Clinical…”

Section: Level Of Evidencementioning

confidence: 99%

“…The Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation (RIVER) study suggested that rivaroxaban was noninferior to warfarin in AF patients with bioprosthetic mitral valves 138 . A meta‐analysis based on RCTs also demonstrated that the use of NOACs, compared to warfarin, significantly reduced the risk of stroke, systemic embolism, and major bleeding in patients with AF and bioprosthetic valves or prior valve repair 139 …”

Section: Stroke Preventionmentioning

confidence: 99%

Chinese guidelines for the diagnosis and management of atrial fibrillation

Ma,

Wu,

Liu

et al. 2024

Pacing Clinical Electrophis

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly impacting patients' quality of life and increasing the risk of death, stroke, heart failure, and dementia. Over the past two decades, there have been significant breakthroughs in AF risk prediction and screening, stroke prevention, rhythm control, catheter ablation, and integrated management. During this period, the scale, quality, and experience of AF management in China have greatly improved, providing a solid foundation for the development of the guidelines for the diagnosis and management of AF. To further promote standardized AF management, and apply new technologies and concepts to clinical practice timely and fully, the Chinese Society of Cardiology of Chinese Medical Association and the Heart Rhythm Committee of Chinese Society of Biomedical Engineering jointly developed the Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation. The guidelines comprehensively elaborated on various aspects of AF management and proposed the CHA2DS2‑VASc‑60 stroke risk score based on the characteristics of the Asian AF population. The guidelines also reevaluated the clinical application of AF screening, emphasized the significance of early rhythm control, and highlighted the central role of catheter ablation in rhythm control.

show abstract

“…[138] A meta-analysis based on RCTs also demonstrated that the use of NOACs, compared to warfarin, significantly reduced the risk of stroke, systemic embolism, and major bleeding in patients with AF and bioprosthetic valves or prior valve repair. [139] The Edoxaban vs. Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation-AF (ENVISAGE-TAVI AF) study demonstrated that when used in AF patients undergoing successful transcatheter aortic valve replacement (TAVR), edoxaban was non-inferior to warfarin in reducing the risk of a postoperative major adverse cardiovascular events. However, the incidence of major bleeding was higher with edoxaban than with vitamin K antagonist.…”

Section: Recommendations Recommendation Grade Level Of Evidencementioning

confidence: 99%

Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

2024

Cardiology Discovery

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, significantly impacting patients’ quality of life and increasing the risk of death, stroke, heart failure, and dementia. Over the past 2 decades, there have been significant breakthroughs in AF risk prediction and screening, stroke prevention, rhythm control, catheter ablation, and integrated management. During this period, the scale, quality, and experience of AF management in China have greatly improved, providing a solid foundation for the development of guidelines for the diagnosis and management of AF. To further promote standardized AF management, and apply new technologies and concepts to clinical practice in a timely and comprehensive manner, the Chinese Society of Cardiology of the Chinese Medical Association and the Heart Rhythm Committee of the Chinese Society of Biomedical Engineering have jointly developed the Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation. The guidelines have comprehensively elaborated on various aspects of AF management and proposed the CHA2DS2-VASc-60 stroke risk score based on the characteristics of AF in the Asian population. The guidelines have also reevaluated the clinical application of AF screening, emphasized the significance of early rhythm control, and highlighted the central role of catheter ablation in rhythm control.

show abstract

Non-Vitamin K Antagonists Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review and Meta-Analysis

Cited by 11 publications

References 30 publications

Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

Chinese guidelines for the diagnosis and management of atrial fibrillation

Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

Contact Info

Product

Resources

About